WallStreetZenWallStreetZen

NASDAQ: APLM
Apollomics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their APLM stock forecasts and price targets.

Forecast return on equity

Is APLM forecast to generate an efficient return?

Company
-28.23%
Industry
12.55%
Market
331.11%
APLM's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is APLM forecast to generate an efficient return on assets?

Company
-10.48%
Industry
11.37%
APLM is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

APLM earnings per share forecast

What is APLM's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.89
Avg 2 year Forecast
-$1.24

APLM revenue forecast

What is APLM's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$1.0M
Avg 2 year Forecast
$0.0

APLM vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
APLM$16.27N/AN/A
MTVA$8.18$132.00+1,513.30%Buy
ALLR$1.14$9.25+711.40%Buy
QNRX$12.09N/AN/A
BLRX$3.38$26.00+669.23%Buy
View Top Biotech Stocks

Apollomics Stock Forecast FAQ

What is APLM's earnings growth forecast for 2025-2026?

(NASDAQ: APLM) Apollomics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 207.1%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 2,947.47%.

Apollomics's earnings in 2025 is -$53,858,000.On average, 3 Wall Street analysts forecast APLM's earnings for 2025 to be -$979,111, with the lowest APLM earnings forecast at -$940,715, and the highest APLM earnings forecast at -$1,007,908.

In 2026, APLM is forecast to generate -$1,373,006 in earnings, with the lowest earnings forecast at -$1,319,163 and the highest earnings forecast at -$1,413,389.

If you're new to stock investing, here's how to buy Apollomics stock.

What is APLM's revenue growth forecast for 2025-2026?

(NASDAQ: APLM) Apollomics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 9,828.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,453.22%.

Apollomics's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast APLM's revenue for 2025 to be $1,125,415, with the lowest APLM revenue forecast at $1,081,281, and the highest APLM revenue forecast at $1,158,515.

In 2026, APLM is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is APLM's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: APLM) forecast ROA is -10.48%, which is lower than the forecast US Biotechnology industry average of 11.37%.

What is APLM's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: APLM) Apollomics's current Earnings Per Share (EPS) is -$52.80. On average, analysts forecast that APLM's EPS will be -$0.89 for 2025, with the lowest EPS forecast at -$0.85, and the highest EPS forecast at -$0.91. In 2026, APLM's EPS is forecast to hit -$1.24 (min: -$1.20, max: -$1.28).

What is APLM's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: APLM) forecast ROE is -28.23%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.